Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the “3 + 7” induction regimen for acute myeloid leukemiaYishai Ofran, Jacob M. Rowe, Ronit Leiba et al.|American Journal of Hematology|2015Cited by 29
MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis – JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib – Preliminary Data From the MANIFEST StudyJohn Mascarenhas, Vikas Gupta, Marina Kremyanskaya et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 13
Early Bone Marrow Examination, On The Fifth Day Of Induction For AML, Is Highly Predictive Of ResponseYishai Ofran, Jacob M. Rowe, Michal Hayun et al.|Blood|2013Cited by 2
Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long‐term follow‐up of a multi‐center prospective studyYishai Ofran, Chezi Ganzel, Michal Hayun et al.|American Journal of Hematology|2019Cited by 1
List of ContributorsGeorge S. Abela, Judit Karácsonyi, Stephen R. Baker et al.|Elsevier eBooks|2018Cited by 0